Skip to main content

Table 2 1-year, 3-year, 5-year survival rate in four cohorts

From: Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database

Items Survival time Survival rate
Mean survival time [95% CI] (months) 1-year survival (95% CI) 3-year survival (95% CI) 5-year survival (95% CI)
Primary hepatic neuroendocrine tumors (PH-NETs): 30.64 (24.75–36.53) 56.43 (48.15–64.36) 30.00 (23.03–38.04) 18.57 (13.00–25.82)
Hepatocellular carcinoma (HCC in situ): 25.11 (20.20–30.02) 55.00 (46.74–63.00) 21.43 (15.44–28.94) 10.71 (6.60–16.93)
Gastrointestinal neuroendocrine tumors in situ (GI-NETs in situ): 41.62 (35.32–47.92) 74.29 (66.47–80.81) 42.86 (34.96–51.14) 27.86 (21.10–35.80)
Gastrointestinal neuroendocrine tumors with liver metastasis (GI-NETs-LM): 24.81 (21.15–36.60) 64.75 (56.51–72.20) 30.94 (23.85–39.05) 8. 63 (5.01–14.48)